Theranostics Australia

Theranostics Australia is a biotechnology company developing integrated molecular imaging and cancer therapy services that is headquartered in East Fremantle, Western Australia and was founded in 2015 by Nat Lenzo.

Theranostics Australia offers several therapy services including: utetium-177 Octreotate therapy, Lutetium-177 PSMA therapy, Radium-223 therapy, Iodine-131 therapy, Yttrium-90 SIRT Therapy, and Yttrium-90 Radiosynovectomy therapy.

Lutetium-177 Octreotate therapy is for treating neuroendocrine tumours (NETs) associated with the endocrine and/or nervous system.

Lutetium-177 PSMA therapy is for treating metastatic or treatment resistant prostate cancer.

Radium-223 therapy is a therapy for treating metastatic prostate cancer that has spread into bone tissue.

A therapy for treating is a therapy for treating thyroid cancer and hyperactive thyroid (thyrotoxicosis) using radiation.

Yttrium-90 SIRT Therapy, also called Selective Internal Radiation Therapy, is a therapy for treating cancers and tumours associated with the liver.

Yttrium-90 Radiosynovectomy therapy is a therapy for treating arthritis and other joint diseases requiring pain relief.